Gastrointestinal Cancer News

Researchers in The Netherlands found that surveillance before hepatocellular carcinoma diagnosis improved overall survival in real-life practice, as well as decreased tumor size and increased surgical therapy time, according to study data published in the Journal of Hepatology. 

Researchers have discovered a new gene, SEC23B, associated with Cowden disease, an inherited disorder that increases risk for thyroid, breast, endometrial and other cancers.

The FDA granted breakthrough therapy designation to pembrolizumab for treatment of patients with microsatellite instability high metastatic colorectal cancer.

Involved-field irradiation therapy reduced toxicity without increasing loco-regional lymph node recurrence compared with elective nodal irradiation among patients with locally advanced esophageal cancer, according to prospective, randomized controlled study results presented at the ASTRO Annual Meeting.

Researchers in Italy found that the use of angiotensin II type 1 receptor blockers known as sartans improved overall survival and delayed time to recurrence for patients with hepatocellular carcinoma, according to published findings.

Endoscopic biliary draining yielded a superior adverse event rate compared with percutaneous drainage among patients with pancreatic cancer, according to the results of a retrospective cohort study.

Combinatory cancer hallmark-based gene signature sets more effectively predicted risk category and RFS than other prognostic predictors for patients with stage II colorectal cancer, according to results of a meta-analysis.

Researchers from The University of Texas MD Anderson Cancer Center found that treatment on the Enhanced Recovery in Liver Surgery pathway enabled patients to recover and return to normal life functioning sooner compared with traditional pathway treatment after liver surgery, according to published findings.

HONOLULU — Study data suggest that urban African Americans are more likely to be diagnosed with advanced pancreatic adenocarcinoma at a younger age and are less likely to receive treatment, according to a presenter at ACG 2015.

Monoclonal antibodies are molecules that are produced by researchers in a lab that target and attack specific antigens, such as those on cancer cells.